These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
221 related articles for article (PubMed ID: 34670633)
41. Predicting changes in substance use following psychedelic experiences: natural language processing of psychedelic session narratives. Cox DJ; Garcia-Romeu A; Johnson MW Am J Drug Alcohol Abuse; 2021 Jul; 47(4):444-454. PubMed ID: 34096403 [No Abstract] [Full Text] [Related]
42. Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function. Johnson MW; Hendricks PS; Barrett FS; Griffiths RR Pharmacol Ther; 2019 May; 197():83-102. PubMed ID: 30521880 [TBL] [Abstract][Full Text] [Related]
43. The Psychedelic Renaissance and Its Forensic Implications. Holoyda B J Am Acad Psychiatry Law; 2020 Mar; 48(1):87-97. PubMed ID: 31948993 [TBL] [Abstract][Full Text] [Related]
44. The Past and Future of Psychedelic Science: An Introduction to This Issue. Doblin RE; Christiansen M; Jerome L; Burge B J Psychoactive Drugs; 2019; 51(2):93-97. PubMed ID: 31132970 [TBL] [Abstract][Full Text] [Related]
45. Psychedelics and music: neuroscience and therapeutic implications. Barrett FS; Preller KH; Kaelen M Int Rev Psychiatry; 2018 Aug; 30(4):350-362. PubMed ID: 30240282 [TBL] [Abstract][Full Text] [Related]
46. Is good science leading the way in the therapeutic use of psychedelic drugs? Hall WD; Humphreys K Psychol Med; 2022 Oct; 52(14):2849-2851. PubMed ID: 36259413 [No Abstract] [Full Text] [Related]
47. The Pharmacology and Clinical Applications of Psychedelic Medicines Within Midwifery Practice. Stein CA; Penn A; Van Hope S; Dorsen CG; Mangini M J Midwifery Womens Health; 2022 May; 67(3):373-383. PubMed ID: 35522087 [TBL] [Abstract][Full Text] [Related]
48. United States National Institutes of Health grant funding for psychedelic-assisted therapy clinical trials from 2006-2020. Barnett BS; Parker SE; Weleff J Int J Drug Policy; 2022 Jan; 99():103473. PubMed ID: 34624734 [TBL] [Abstract][Full Text] [Related]
49. Classical Psychedelics as Therapeutics in Psychiatry - Current Clinical Evidence and Potential Therapeutic Mechanisms in Substance Use and Mood Disorders. Mertens LJ; Preller KH Pharmacopsychiatry; 2021 Jul; 54(4):176-190. PubMed ID: 33472250 [TBL] [Abstract][Full Text] [Related]
50. Psychedelics in the treatment of unipolar mood disorders: a systematic review. Rucker JJ; Jelen LA; Flynn S; Frowde KD; Young AH J Psychopharmacol; 2016 Dec; 30(12):1220-1229. PubMed ID: 27856684 [TBL] [Abstract][Full Text] [Related]
51. Illicit use of LSD or psilocybin, but not MDMA or nonpsychedelic drugs, is associated with mystical experiences in a dose-dependent manner. Lyvers M; Meester M J Psychoactive Drugs; 2012; 44(5):410-7. PubMed ID: 23457892 [TBL] [Abstract][Full Text] [Related]
53. A review of lysergic acid diethylamide (LSD) in the treatment of addictions: historical perspectives and future prospects. Liester MB Curr Drug Abuse Rev; 2014; 7(3):146-56. PubMed ID: 25563445 [TBL] [Abstract][Full Text] [Related]
59. From Psychiatry to Flower Power and Back Again: The Amazing Story of Lysergic Acid Diethylamide. Mucke HA Assay Drug Dev Technol; 2016 Jul; 14(5):276-281. PubMed ID: 27392130 [TBL] [Abstract][Full Text] [Related]
60. Psychedelic drugs should be legally reclassified so that researchers can investigate their therapeutic potential. Rucker JJ BMJ; 2015 May; 350():h2902. PubMed ID: 26014506 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]